Tags : Biothera

Insights+

Insights+ Key Biosimilars Events of September 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Aug 31 – Sept 04, 2020)

1. AbbVie to License I-Mab’s Lemzoparlimab (TJC4) for ~$2B Published: Sept 04, 2020 | Tags: AbbVie, License, I-Mab, Lemzoparlimab, (TJC4), ~$2B 2. Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia Published: Sept 03, 2020 | Tags: Kite, HiFiBiO Therapeutics, Collaborate, Antibodies, Targeting, Acute Myeloid Leukemia 3. Abbott Initiates LIFE-BTK Trial to […]Read More

Biosimilars Insights+

Insights+ Key Biosimilars Events of January 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, Pfizer launched its two biosimilars [Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab)] at lowest WAC in the US Our team at PharmaShots has summarized key […]Read More